Roche Holding AG (RHHBY)
30.05
-0.03
(-0.10%)
USD |
OTCM |
Apr 18, 16:00
Roche Enterprise Value: 218.62B for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | 218.62B |
| April 17, 2024 | 218.81B |
| April 16, 2024 | 219.77B |
| April 15, 2024 | 222.00B |
| April 12, 2024 | 222.06B |
| April 11, 2024 | 224.42B |
| April 10, 2024 | 222.06B |
| April 09, 2024 | 222.51B |
| April 08, 2024 | 219.51B |
| April 05, 2024 | 219.83B |
| April 04, 2024 | 223.08B |
| April 03, 2024 | 226.59B |
| April 02, 2024 | 227.10B |
| April 01, 2024 | 230.74B |
| March 28, 2024 | 230.55B |
| March 27, 2024 | 226.66B |
| March 26, 2024 | 226.66B |
| March 25, 2024 | 226.53B |
| March 22, 2024 | 226.72B |
| March 21, 2024 | 226.72B |
| March 20, 2024 | 235.01B |
| March 19, 2024 | 231.82B |
| March 18, 2024 | 232.20B |
| March 15, 2024 | 235.14B |
| March 14, 2024 | 236.73B |
| Date | Value |
|---|---|
| March 13, 2024 | 245.22B |
| March 12, 2024 | 251.15B |
| March 11, 2024 | 247.70B |
| March 08, 2024 | 243.17B |
| March 07, 2024 | 242.35B |
| March 06, 2024 | 240.43B |
| March 05, 2024 | 238.39B |
| March 04, 2024 | 236.67B |
| March 01, 2024 | 237.94B |
| February 29, 2024 | 235.71B |
| February 28, 2024 | 236.99B |
| February 27, 2024 | 237.63B |
| February 26, 2024 | 234.37B |
| February 23, 2024 | 237.18B |
| February 22, 2024 | 234.18B |
| February 21, 2024 | 236.86B |
| February 20, 2024 | 235.78B |
| February 16, 2024 | 232.84B |
| February 15, 2024 | 231.69B |
| February 14, 2024 | 231.18B |
| February 13, 2024 | 231.89B |
| February 12, 2024 | 234.88B |
| February 09, 2024 | 233.03B |
| February 08, 2024 | 231.69B |
| February 07, 2024 | 234.56B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
218.62B
Minimum
Apr 18 2024
368.95B
Maximum
Dec 28 2021
287.66B
Average
287.61B
Median
Enterprise Value Benchmarks
| Novartis AG | 199.86B |
| Pfizer Inc | 201.80B |
| Eli Lilly and Co | 731.61B |
| ADC Therapeutics SA | 226.97M |
| AC Immune SA | 112.70M |
Enterprise Value Related Metrics
| Earnings Yield | 6.66% |
| Operating Earnings Yield | 8.91% |
| Normalized Earnings Yield | 6.737 |